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Abstract
Background: Activator Protein-2 (AP-2) transcription factors are critically involved in a variety of fundamental
cellular processes such as proliferation, differentiation and apoptosis and have also been implicated in
carcinogenesis. Expression of the family members AP-2a and AP-2g is particularly well documented in malignancies
of the female breast. Despite increasing evaluation of single AP-2 isoforms in mammary tumors the functional role
of concerted expression of multiple AP-2 isoforms in breast cancer remains to be elucidated. AP-2 proteins can
form homo- or heterodimers, and there is growing evidence that the net effect whether a cell will proliferate,
undergo apoptosis or differentiate is partly dependent on the balance between different AP-2 isoforms.
Methods: We simultaneously interfered with all AP-2 isoforms expressed in ErbB-2-positive murine N202.1A breast
cancer cells by conditionally over-expressing a dominant-negative AP-2 mutant.
Results: We show that interference with AP-2 protein function lead to reduced cell number, induced apoptosis
and increased chemo- and radiation-sensitivity. Analysis of global gene expression changes upon interference with
AP-2 proteins identified 139 modulated genes (90 up-regulated, 49 down-regulated) compared with control cells.
Gene Ontology (GO) investigations for these genes revealed Cell Death and Cell Adhesion and Migration as the
main functional categories including 25 and 12 genes, respectively. By using information obtained from Ingenuity
Pathway Analysis Systems we were able to present proven or potential connections between AP-2 regulated genes
involved in cell death and response to chemo- and radiation therapy, (i.e. Ctgf, Nrp1, Tnfaip3, Gsta3) and AP-2 and
other main apoptosis players and to create a unique network.
Conclusions: Expression of AP-2 transcription factors in breast cancer cells supports proliferation and contributes
to chemo- and radiation-resistance of tumor cells by impairing the ability to induce apoptosis. Therefore,
interference with AP-2 function could increase the sensitivity of tumor cells towards therapeutic intervention.
Background
The familiy of Activator Proteins-2 (AP-2, Tcfap2) com-
prises 5 highly conserved DNA-binding transcription
factors referred to as AP-2a,A P - 2 b,A P - 2 g,A P - 2 δ and
AP-2ε (or Tcfap2a-e) [1]. They preferentially bind GC-
rich consensus-sequences in their target genes, which
results in transcriptional regulation either as a stimula-
tory or repressive event [1,2]. All AP-2 proteins share a
modular protein structure consisting of a proline/gluta-
mine-rich transactivation domain at the amino terminus,
followed by a highly conserved central basic region
and a helix-span-helix motif at the carboxyl terminus.
DNA-binding is mediated by the basic region and
requires dimer formation of two AP-2 proteins via the
helix-span-helix motifs. AP-2 proteins are involved in
manifold cellular functions such as proliferation,
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any medium, provided the original work is properly cited.differentiation and apoptosis and play pivotal roles dur-
ing embryonic development and carcinogenesis [1].
Especially the family members AP-2a and AP-2g have
been implicated in breast cancer [3]. Under physiologi-
cal conditions expression of AP-2a and AP-2g is
restricted to either the luminal or the myoepithelial
compartment in the breast, respectively [4,5]. In contrast
simultaneous overexpression of AP-2a and AP-2g has
been observed in breast carcinoma [4], but their impact
on mammary tumorigenesis is still discussed controver-
sially [6].
Several studies propose a tumor-suppressive function
for AP-2a in breast tissue [7-9] and data from clinical
trials indicate that tumor progression is accompanied by
loss of AP-2a expression [10]. Moreover, loss of hetero-
zygosity on chromosome position 6p22, where AP-2a is
mapped to, is frequently observed in breast cancer spe-
cimens [11]. Accordingly, high expression of AP-2a in
invasive breast cancer is correlated with favorable overall
survival rates in patients [4].
Furthermore, in transgenic mouse studies, overexpres-
sion of AP-2a in the mammary epithelium resulted in
impaired mammary gland growth caused by a reduction
in proliferation and a simultaneous increase in apoptosis
[12]. This fits in vitro data where loss of AP-2a lead to
a decrease of apoptosis and an increased resistance
towards chemotherapeutic drugs [8]. These effects
might be partly mediated through control of expression
of the CdK-Inhibitor p21
WAF and of p53 by AP-2a,
which supports the idea that AP-2a acts as a tumor
suppressor [9,13,14].
In contrast, little is known about the actual role of
AP-2g in breast carcinogenesis. Overexpression of AP-
2g is frequently seen in breast tumors and breast can-
cer cell lines [15,16] and has recently been shown to
correlate with poorer response to hormone therapy
and reduced patient survival in invasive breast cancer
[17,18]. In addition, increased expression of AP-2g has
been associated with poorly differentiated breast tumor
samples [4]. Gene amplification has been proposed as
potential mechanism leading to overexpression of AP-
2g because the gene maps to the genomic locus
20q13.2, which is frequently amplified in breast cancer
[19]. Transgenic mouse studies provide further evi-
d e n c ef o rar o l eo fA P - 2 g in breast tumor formation:
MMTV-driven overexpression of AP-2g in the mam-
mary epithelium leads to increase in proliferation and
an impaired differentiation [20]. Moreover, bi-
transgenic mice expressing the oncogenic HER-2/neu
receptor tyrosine kinase and AP-2g showed an acceler-
ated tumor progression compared to single-transgenic
HER-2/neu mice [21]. Together, these findings point
towards a causal involvement of AP-2g in the etiology
of breast cancer.
AP-2 proteins form either homo- or heterodimers [1].
T h e r ei se v i d e n c et h a tu n d e rphysiological conditions
the net effect whether a cell proliferates, undergoes
apoptosis or differentiates, may depend on the balance
between different AP-2 isoforms [22]. So far, experi-
ments addressing AP-2 functions in breast cancer cells
were using either overexpression of, or interference with
particular AP-2 isoforms. Overexpression of transcrip-
tion factors may lead to occupancy of promoters not
used under physiological conditions, which masks speci-
fic AP-2 functions. In the latter case, interference with a
particular isoform may cause a shift in AP-2 dimer com-
position and hence obscure the physiological function.
In a complementary approach, we now set out to
investigate the role of AP-2 proteins in a global manner
by interfering with them functionally. To this end, we
conditionally overexpressed a dominant-negative mutant
(ΔAP-2g) in the N202.1A murine breast cancer cell line
expressing AP-2a and AP-2g endogenously. Interference
with AP-2 proteins influenced the expression of genes
involved in chemo- and radiation-sensitivity and
resulted in the induction of apoptosis. These results
establish an important role for AP-2 transcription fac-
tors in breast cancer cells determining their sensitivity
towards chemotherapeutic agents and ionizing radiation.
Expression of AP-2 proteins in breast tumors might
therefore be of prognostic value. The results also suggest
that AP-2 proteins or their target genes may be promis-
ing targets for therapeutic intervention in breast cancer.
Methods
Plasmids
pUHG172-1neo (rtTA) was kindly provided by
H. Bujard (Heidelberg, Germany). In order to yield
pBIEGFP, EGFP was cloned from pEGFP-C3 into pBI-4
(kindly provided by H. Bujard (Heidelberg, Germany) as
an NheI/XbaI fragment. ΔAP-2g was created by deleting
474 bp (158 aa of the NH-terminus) of the 5’-portion of
the murine AP-2g cDNA. Upon introduction of a start
codon using a NotI/NaeI-flanked oligo, ΔAP-2g was
cloned into pBIEGFP using NotI/Sal I restriction sites to
generate pBIEGFPΔAP-2g. The BMP-4 Firefly luciferase
construct was kindly provided by M. Moser, (Martins-
ried, Germany) and the CMV-Renilla luciferase plasmid
was obtained from Promega (Mannheim, Germany).
Cell Lines and Cell Culture
The murine breast cancer cell line N202.1A is derived
from MMTV-HER-2/neu transgenic mice and was
kindly provided by P.-L. Lollini (Bologna, Italy) [22].
N202.1A cells were grown in DMEM-Glutamax supple-
mented with 20% fetal calf serum and penicillin/strepto-
mycin (Invitrogen, Karlsruhe, Germany). Cells were kept
under standard conditions using a cell culture type
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Page 2 of 15incubator at 37°C under 7.5% CO2. Functional assays
were performed 96 h after addition of doxycycline to
the cell culture media (2 μg/ml, BD Biosciences, Heidel-
berg, Germany).
Transient and stable Transfection
For stable transfection N202.1A cells were transfected
using 39 μg plasmid DNA (ratio plasmid - resistance
gene 10: 1) using 107.5 μl Lipofectamine 2000 (Invitro-
gen, Karlsruhe, Germany) per 10 cm culture dish
according to the manufacturer’s protocol. N202.1A cells
were selected at 850 μg/ml G418 (Calbiochem, Darm-
stadt, Germany) for the pUHG172-1neo and 200 μg/ml
Hygromycin B (BD Biosciences, Heidelberg, Germany)
for pBIEGFPΔAP-2g and pBIEGFP. For BMP-4 lucifer-
ase assays N202.1A cells were transfected with 900 ng
plasmid (870 ng BMP-4 Firefly luc +30 ng CMV-Renilla
luc) and 1.75 μl Lipofectamine 2000 (Invitrogen, Man-
nheim, Germany) per 24 well culture dish according to
the manufacturer’s protocol.
Microscopy and Image Processing
Cells were visualized using a Leica-DM-IRB microscope
(Bensheim, Germany), fitted to a Microfire digital cam-
era (Optronics, Goleta, CA, USA) and image processing
was performed applying Adobe Photoshop and Illustra-
tor software.
Co-Immunoprecipitation
HCT116 cells were transfected with equal amounts of
AP-2a-a n dΔAP-2g - expression plasmids. Cells were
lysed after 48 hours with non-denaturing lysis buffer.
Co-IP was performed with 20 μl DYNABEADS®(Invitro-
gen Cat.no. 199.03D, Invitrogen, Karlsruhe, Germany)
und 1,5 μga n t i - A P - 2 a antibody (H79, Santa Cruz, Hei-
delberg, Germany). 150 μg protein lysate per sample
was loaded. Western blot with anti-AP-2g antibody
(6E4/4, Santa Cruz, Heidelberg, Germany) followed.
Western Blot Analysis, Luciferase Assays and Giemsa
Staining
Western Blot was performed using the following pri-
mary antibodies: AP-2g (6E4/4, 1:200 Upstate, New
York, USA), AP-2a (H79, 1:200 Santa Cruz Heidelberg,
Germany), AP-2b (1:1000), AP-2δ (1:1500) and AP-2ε
(1:1500), all kindly provided by M. Moser (Martinsried,
Germany). The following secondary antibodies were
used: goat anti-rabbit-HRP (1:2000 DAKO, Hamburg,
Germany) and rabbit anti-mouse HRP (1:1000, DAKO,
Hamburg, Germany). Protein lysates from HeLa (cervi-
cal carcinoma) N2A (neuroblastoma) cell lines and
human keratinocytes or in vitro synthesized proteins,
respectively, served as antibody positive controls for the
different AP-2 isoforms in Western Blot analysis. BMP-
4 promoter luciferase assays were performed using the
“Dual Luciferase Reporter Assay Systems Kit” (Promega,
Mannheim, Germany) according to the manufacturer’s
protocol. 48 h upon induction (2 μg/ml doxycycline),
N202.1A cells were transfected with BMP-4-Firefly luc,
lysed, and luciferase activity was measured at 562 nm
(Berthold Technologies, Bad Wildbad, Germany). Trans-
fection efficiencies were normalized using a CMV-driven
Renilla Luciferase (CMV-Renilla luc). To quantifiy cell
numbers after treatment with chemotherapeutic com-
pounds and irradiation cells were stained with Giemsa.
For this purpose cells were washed twice in ice-cold
PBS and fixed in methanol for 5 min at room tempera-
ture, stained for 5 min in Giemsa solution (Merck,
Darmstadt, Germany) and washed gently in H2O. Cells
were quantified using ImageJ software (Adriamycin
treatment) or three independent fields of visions were
counted (irradiation) in each experiment.
Proliferation
Determination of S-phase index was carried out using
the “Click-iT™ EdU Imaging Kit” (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Briefly, 96 h after addition of doxycycline (2 μg/ml)
N202.1A cells were incubated with 100 μM thymidine
analogon EdU for 30 min at 37°C, fixed in 3.7% formal-
dehyde for 15 min and washed twice in 3% BSA/PBS.
Permeabilization was achieved using 0.5% Triton X-100/
PBS for 20 min and cells were washed twice with 3%
BSA/PBS. Subsequently, the fixed cells were incubated
with the reaction cocktail containing Alexa Fluor®594-
azide for 30 min and washed with 3% BSA/PBS. Imaging
using a Leica DM-IRB (Leica, Bensheim, Germany)
microscope was followed by quantification of Edu Alexa
Fluor®594-azide staining in three fields of vision (magni-
fication ×100) in three independent experiments. On
average, a field of vision contained 218 cells.
Transmission (TEM) - and scanning electron microscopy
(SEM)
For TEM-analysis, cells were fixed in 1.25% glutaralalde-
hyde in 0.1 M cacodylate buffer (pH 7.4) for 1 h and
post-fixed in 2% OsO4 in cacodylate. Following dehydra-
tion in a graded series of ethanol, the specimens were
embedded in a propylene-epon-mixture, mounted as
50 nm thin sections and post-contrasted with 3.5% ura-
nylacetate. TEM analysis was performed using a CM10
microscope (Philips, Eindhoven, Netherland).
For SEM cells were fixed in 2% glutaralaldehyde in
0.1 M sodium cacodylate (pH 7.3) for 20 min, trans-
ferred to 0.1% aqueous tannic acid and rinsed with dis-
tilled water. All specimens were dehydrated through
a graded series of ethanol and critical point-
dried from CO2 in 10 cycles using a Balzers CPD 030
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were mounted on aluminium sample holders and coated
with a 2 nm layer of platinum/palladium in a HE 208
sputter coating device (Cressington, Watford, UK). SEM
analyis was performed with an XL 30 SFEG (Philips,
Eindhoven, Netherlands).
Caspase 3/7 Acitivity and AnnexinVC3.18 staining
Caspase 3/7 activity was quantified using the “Caspase-
Glo® 3/7 Assay Kit” (Promega, Mannheim, Germany)
according to manufacturer’s instructions. Non-induced
or cells induced with doxycycline (2 μg/ml) for 96 h
were incubated with “Caspase-Glo® 3/7 Reagent” for 3 h
followed by measurement of luminescence at 562 nm
(Berthold Technologies, Bad Wildbad, Germany).
AnnexinVC3.18 staining was carried out using the
“AnnexinVC.18 Kit” (Sigma-Aldrich, Munich, Germany).
Doxycycline-induced cells were washed 3 times in PBS
followed by 3 cycles of binding buffer for 1 min. In the
next step cells were incubated with the AnnexinVC3.18
conjugate (AnnexinVC3.18:binding buffer, 1:100) for
10 min at room temperature, washed 3 times in binding
buffer and then subjected to fluorescence microscopy.
Cells treated for 2.5 h with Staurosporine (2 μM) served
as positive controls (Sigma-Aldrich, Munich, Germany).
Irradiation
The irradiation of the N202.1 cells 96 h after addition of
doxycyline (2 μg/ml) at 105 Gy was performed using a
linear accelerator (Siemens Mevaton MD2, Siemens
Medizintechnik, Munich, Germany). The photon energy
of 6 MeV at a dose rate of 2 Gy/min was chosen. The
field size was set to 20 cm × 20 cm at a SSD (skin to
surface distance) of 100 cm. The beam divergence was
approx. 11°. The cells were irradiated in a 6-well plate
using a RW3-Phantom (PTW) at dose maximum. The
photon beam was calibrated according the DIN 6800-2
protocol for a water equivalent energy dose. The RBW-
factor for 6 MeV irradiation is almost 1, so the energy
dose was equivalent to the biological dose.
RNA isolation and qRT-PCR
Total RNA was isolated from the various clones using Tri-
zol Reagent (Invitrogen, Karlsruhe, Germany) according to
the manufacturer’si n s t r u c t i o n s .1μg of DNase-treated
(DNA-free™ kit, Ambion, Austin, TX) total RNA was
reverse transcribed using RETROscript™ reagents
(Ambion, Austin, TX). RNA was heat-denatured for 3’ at
85°C and the reaction was incubated at 42°C for 1 hour
and 10' at 92°C. Quantitative Real Time PCR (qRT-PCR)
reactions were carried out in 96 well plates using SYBR-
Green®Master Mix (Applied Biosystems, Foster City, CA),
specific primers and 10 ng total RNA converted into
cDNA in 10 μl final volume. Fluorescence was measured
using an ABI Prism® 7300 (Applied Biosystems, Foster
City, CA) detection system according to the manufac-
turer’s instructions. Primers were purchased from QIA-
GEN (QuantiTect® Primer Assays). Relative quantitations
to control cells were performed: first, each Ct value was
corrected for the Ctr of the reference gene, GAPDH, and
then the Ct of each sample was subtracted from the Ct of
control cells (Ct0). The relative amount of template (Q)
was therefore calculated as: Q
Ct Ct Ct Ct r r =
−− − − 2 00 () ( ) .A l l
samples were run in triplicates and mean and standard
deviation calculated as described in Bookout et al. 2003
[23]. QuantiTect® Primer Assay catalogue numbers are as
follows: QT00101297 Mm_Tcfap2c_1_SG QuantiTect
Primer Assay (200) (NM_009335, NM_001159696);
QT00265524 Mm_Egr3_1_SG QuantiTect Primer Assay
(200) (NM_018781); QT00096131 Mm_Ctgf_1_SG Quan-
tiTect Primer Assay (200) (NM_010217); QT01044295
Mm_Sema3b_1_SG QuantiTect Primer Assay (200)
(NM_009153); QT00157381 Mm_Nrp1_1_SG QuantiTect
Primer Assay (200) (NM_008737); QT01061599
Mm_Gsta3_1_SG QuantiTect Primer Assay (200)
(NM_010356); QT00100653 Mm_Gzme_1_SG Quanti-
Tect Primer Assay (200) (NM_010373); QT00134064
Mm_Tnfaip3_1_SG QuantiTect Primer Assay (200)
(NM_009397). QT00105483 Mm_Fst_1_SG QuantiTect
Primer Assay (200) (NM_008046).
Northern Blot
Northern Blot analysis was carried out as described in
Jäger et al. [20] using the murine AP-2g cDNA as a
probe.
Whole genome expression analysis
Microarray analysis of gene expression in response to
expression of ΔAP-2g/EGFP (Δ#7 + Δ#15) or EGFP
(Δ#5 + Δ#11) in N202.1A breast cancer clones (2 μg/ml
doxycyline for 96 h) was performed using the Illumina
BeadChip system (Illumina, Inc, San Diego, CA). We
used 500 ng of total RNA to obtain labeled, amplified
cRNA for each sample to hybridize the Illumina Ref-8
BeadChips according to manufacturer’s instructions
(Illumina, Inc, San Diego, CA). Arrays were scanned
with an IlluminaBeadArray Reader confocal scanner and
data processed and analyzed using IlluminaBeadStudio
software (Illumina, Inc, San Diego, CA). Raw Illumina
data were rank invariant normalized with BeadStudio
software (Illumina, Inc, San Diego, CA), which was also
used to assess differential expression between the ΔAP-
2g and control clones, based on three RNA preparations
from each clone after subtraction of the background
obtained with control clones following doxycyclin treat-
ment. After normalization, g e n e sw e r ef i l t e r e db yt h e i r
‘detection’ value, which had to be 0.99 (significantly
detected), in the three samples. Subsequently, we
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mina custom error model implemented in BeadStudio,
which provides an expression difference score (‘Diff-
Score’) taking into account background noise and sam-
p l ev a r i a b i l i t y[ 2 4 ] .W ec h o s eaD i f f S c o r et h r e s h o l do f
30, corresponding to a p value of 0.001, with a False
Discovery Rate (FDR) lower than 5%. To restrict the
analysis to the most regulated genes, an additional filter-
ing criterion was that the average expression fold-
change between ΔAP-2g/EGFP- (Δ#7 or Δ#15) and
EGFP- (Δ#5 or Δ#11) expressing clones had to be at
least 1.5-fold, which lead to the identification of 139
modulated transcripts (49 decreased and 90 increased).
Sample permutation analysis confirmed that under these
conditions the FDR was well below 5%.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) is a computa-
tional method used to look for overlaps between
the AP-2-driven gene set obtained from the microarray
analysis and modulated genes present in the Molecular
Signature Database (MSigDB) following chemical and
genetic perturbations [25].
Chromatin immunoprecipitation (ChIP) assays
ChIP was performed using the ChIP-IT™ Kit (Active
Motif, Carlsbad, CA) reagents and protocols. Primer
pairs were designed on the TFAP2 binding site contain-
ing regions (identified by TRANSFAC) using the Pri-
mer-BLAST software http://www.ncbi.nlm.nih.gov/tools/
primer-blast/index.cgi?LINK_LOC=NcbiHomeAd. The
following primers were used: Tnfaip3FW: 5'-
CCCCTAACGGAGGCACTCTTCCAC-3'; Tnfaip3RV:
5'-CCGCCTCCTCCAGGTCTTCCTAGCCC-3'; Ctgf
FW: 5'-AGGAAGTCTC GGGCCTCTTCTCTTTGA-3';
CtgfRV: 5'-TCAAGTGGCTGACCACATCATCTG
CAC-3'.
PCR was performed using Platinum® Taq DNA Poly-
merase according to the manufacturer’s instructions.
Results
Establishment of N202.1A breast cancer cells
conditionally expressing ΔAP-2g using the Tet-ON®
System
To assess the role of AP-2 proteins in breast cancer we
took advantage of the murine N202.1A breast cancer
cell line [26], which had been derived from a mammary
tumor of a MMTV-HER-2/neu transgenic mouse and
expresses AP-2a and AP-2g. To functionally interfere
with AP-2 proteins, we constructed a dominant-negative
mutant of the transcription factor AP-2 (Figure 1A). For
this purpose we used a truncated cDNA of the murine
AP-2g lacking the 5’-portion, which encodes the 158
amino acids of the transactivation domain. This mutant,
referred to as ΔAP-2g (Figure 1B), is still able to dimer-
ize but fails to regulate target genes due to the lack of
its transactivation domain. It therefore interferes with
AP-2 function in a dominant-negative manner [27,28].
Conditional expression of the ΔAP-2g construct was
achieved using the Tet-ON® System with a bidirectional
promoter allowing for simultaneous expression of the
dominant-negative AP-2g molecule (ΔAP-2g)a n dt h e
reporter Enhanced Green Fluorescent Protein (EGFP,
Figure 1C) in a doxycycline-dependent manner
(Figure 1D). Stable transfection of N202.1A cells with
these constructs yielded clones conditionally coexpres-
sing the ΔAP-2g and EGFP upon addition of doxycycline
(Figure 1E, G compare to inset). To exclude clonal
effects due to different copy numbers or integration
sites of the transfected constructs all analyses were per-
formed with two independently derived clones (Δ#7,
Δ#15). Furthermore we created control clones, condi-
tionally expressing only EGFP (Co#5, Co#11), in order
to exclude unspecific effects caused by EGFP expression
or by doxycycline treatment (Figure 1F, H, compare to
inset).
Western blot analyses demonstrated the expression of
AP-2a and little amounts AP-2δ in N202.1A cells
(Figure 2A). Subsequent northern- and western blot
analyses showed expression of AP-2g in the cells and
further documented, that the clones strongly over-
express ΔAP-2g both on RNA and on protein level after
addition of doxycycline. Of note, no band indicative of
expression of ΔAP-2g could be detected in the absence
of doxycline. Also, expression of ΔAP-2g did not affect
the level of endogenous AP-2g (Figure 2B, C). Using
CoIP we demonstrated the ability of the truncated ΔAP-
2g molecule to heterodimerize with AP-2a as well
(Figure 2D). To confirm the functionality of ΔAP-2g,w e
performed a luciferase reporter assay using a BMP-4
promoter element. BMP-4 expression is modulated by
AP-2 transcription factors (unpublished data). The
expression of ΔAP-2g significantly reduced the luciferase
signal in the ΔAP-2g (P < 0.01) clones but not in
controls (Figure 2E). Therefore we have established a
system which allows for functional interference with
AP-2 transcription factors in N202.1A mammary tumor
cells.
Whole genome expression analysis and target gene
identification
To better understand the role of AP-2 transcription fac-
tors in initiation and progression of breast cancer, we
set out to identify AP-2 regulated genes using whole
genome expression analysis. The global patterns of gene
expression were analyzed in ΔAP-2g expressing (#7 and
#15) clones versus control (#5 and #11) clones in pre-
sence of doxycycline. In total 139 differentially expressed
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Page 5 of 15Figure 1 Establishment of the conditional ΔAP-2g expression system using the Tet-ON® System in N202.1A breast cancer cells. (A) The
schematic representation of the structural AP-2 protein domains shows the N’-terminal proline- and glutamine-rich (PY) transactivation domain,
the DNA-binding domain which consists of the basic region and the helix-span-helix motif and the C’-terminal dimerization domain. (B) The
dominant-negative AP-2g mutant (ΔAP-2g) has a deleted transactivation domain and therefore an abolished transactivation potential. It still
dimerizes with full length AP-2 proteins, thereby inhibiting their function. (C, D) Usage of a bidirectional Tet Responsive Element promoter (TRE)
allowed for conditional coexpression of ΔAP-2g and EGFP upon addition of doxycycline (+dox, 2 μg/ml) in rtTA containing N202.1A cells. (E-H)
Generation of N202.1A clones expressing ΔAP-2g and/or EGFP respectively: stably transfected N202.1A rtTA breast cancer cells were screened for
conditional expression of rtTA and either ΔAP-2g and EGFP (E, Δ#7) or EGFP only (F, Co#11) using fluorescence (E, F) and phase contrast (G, H)
microscopy. Clones display a low backround expression in the uninduced state (-dox) but high transgene expression upon induction (+dox,
2 μg/ml). Scale Bar in E-H represents 50 μm.
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Page 6 of 15Figure 2 AP-2 isoform and conditional ΔAP-2g expression in N202.1A cells. Verification of ΔAP-2g function using BMP-4 luciferase
promoter assays. (A) Western-blot using antibodies detecting the different AP-2 isoforms in N202.1A cells. As positive control (Pos) for the
antibodies, we used protein lysate from HeLa cells for AP-2a (HeLa), N2A cells for AP-2δ (N2A), human Keratinocytes for AP-2ε (hum Ker) and in
vitro translated protein for AP-2b (iv). (B) Northern blot analysis of ΔAP-2g expression in the stable N202.1A clones, uninduced or induced with
doxycycline (2 μg/ml). Fifteen micrograms of total RNA were resolved on a formaldehyde gel, transferred to a Nylon membrane and hybridized
with a P-32-labelled AP-2g cDNA probe. GAPDH probe was used to monitor the amounts of RNA. (C) N202.1A cells were induced with
doxycycline (2 μg/ml) for 96h and subjected to western blot analysis. Δ#7 and Δ#15 show strong transgene expression in a doxycyline
dependent-manner (32 kDa), which is not detectable in Co#5 and Co#11. Of note, the antibody also detects endogeneous AP-2g (50 kDa) which
is not affected by doxycycline. (D) HCT116 cells were transfected with expression constructs for AP-2a and ΔAP-2g. Co-IP experiment using
antibody to AP-2g for IP and antibody to AP-2a to detect heterodimerization between ΔAP-2g and AP-2a. - no Antibody; + IP using AP-2g
Antibody; input control. (E) For BMP-4-promoter luciferase assays N202.1A cells were induced with doxycycline for 96 h and transfected with
BMP-4 luciferase. 48 h after transfection luciferase activity was quantified. For internal normalization of transfection efficiency a CMV-driven renilla
luciferase was used.
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to promoter occupancy, the promoter regions of 96
genes were analyzed using Transfac analyses to define
consensus binding sites for AP-2 proteins. Of these 96
candidate genes, 52 genes displayed AP-2 binding sites
indicating a direct regulation (additional file 1:
Table S1). Sequence alignments revealed, that 23 of the
52 binding sites are conserved between mouse and
human, further suggesting a functional role for AP-2 in
regulating these genes. (additional file 1: Table S1, genes
marked in red). To investigate whether AP-2 transcrip-
tion factors directly bind to these target genes ‘in vivo’
chromatin immunoprecipitation was performed on pro-
moter elements of Connective Tissue Growth Factor
(Ctgf) and Tumor necrosis factor alpha-induced protein
3( T n f a i p 3 ) .B o t hA P - 2 a and AP-2g are recruited to
promoter regions of these genes, confirming a direct
regulation (Figure 3A). Differentially expressed genes
were distributed in different Gene Ontology (GO)
classes, the main one being cell death (25 genes), fol-
lowed by cell adhesion and cell movement (12 genes),
and nucleosome assembly (8 genes). In particular, sev-
eral cell death players were found and listed in Table 1.
Among them C o n n e c t i v eT i s s u eG r o w t hF a c t o r( C t g f ) ,
Neuropilin1 (Nrp1), Chemokine C-C motif ligand
9( C c l 9 )and Tumor necrosis factor alpha-induced pro-
tein 3 (Tnfaip3) were highly up-regulated suggesting a
repressive role of AP-2 on these genes. On the other
hand Semaphorin 3B (Sema3b) and Early Growth
Response 3 (Egr3) were strongly down-regulated suggest-
ing an activating function of AP-2 on these genes.
Microarray data were validated by qRT-PCR performed
on three different RNA preparations for each clone for
6 genes involved in cell death and for 3 genes belonging
to other GO classes, all showing a fold change (FC) >2.0
(Figure3B). Differential gene expression obtained from
microarray analysis was compared with data resulting
from clones Δ#7 and Δ#15 versus Co#5 and Co#11 or
from clone Δ#7 versus Co#11. Data were normalized
using the GAPDH gene as internal control. Using some
of the information obtained with Ingenuity™ Pathway
Analysis Systems we were able to build a simplified net-
work for genes involved in cell death (Figure 3C).
Gene Set Enrichment Analysis
By using the computational Gene Set Enrichment Ana-
lysis (GSEA) we looked for gene overlaps between
our AP-2-dependent differentially expressed genes
(additional file 1: Table 1) and a collection of twenty
chemical and genetic perturbation gene datasets span-
ning 16,271 genes present in the Molecular Signature
Database (MSigDB, http://www.broadinstitute.org/gsea/
msigdb/) [25]. Results are reported in additional file 2:
Table 2, where we found that modulation of the AP-2
dependent genes, such as thrombospondin 1, tumor
necrosis factor, alpha-induced protein 3, jagged 1, sema-
phorin3B, early growth response3, anillin, collagen type
X alpha 1, hydroxysteroid(11-beta)dehydrogenase 1 have
also been found in collections of up- or down-regulated
genes following chemical and genetic perturbations.
These findings reinforce the involvement of AP-2-driven
genes with apoptosis and chemo- and radiation-
sensitivity.
Interference with AP-2 proteins increases the chemo- and
radiation-sensitivity of N202.1A breast cancer cells
The global gene expression analysis also identified
AP-2 regulated genes, which have an impact on sensi-
tivity of cancer cells towards chemotherapeutic drugs
and irradiation like for example the ATP-binding-
cassette, subfamilyB (MDR/TAP) member 9 and
GSTA3 ( F i g u r e3 B )[ 2 9 , 3 0 ] .T h e r e f o r ew et e s t e d
whether interference with AP-2 proteins has an influ-
ence on the chemo- and radiation-sensitivity of
N202.1A breast cancer cells.
For this purpose the cells were induced with doxy-
cycline for 96 h and then additionally treated with che-
motherapeutic drugs. 72 h after treatment with the
topoisomerase II inhibitor Adriamycin, the ΔAP-2g
expressing clones showed an apparent change in mor-
phology; they displayed a more roundish morphology
(Figure 4A) compared to the non-induced cells or con-
trol cells, which retained a healthy polygonal morpho-
logy. After 72 h the cell numbers had dropped to
approximately 60% in the cultures where ΔAP-2g was
expressed compared to controls (Figure 4B) (p = 0.009).
A similar trend was observed after treatment with
Etoposide and Cisplatin (data not shown). These data
indicate that repression of AP-2 protein function results
in enhanced sensitivity towards chemotherapeutic drugs
such as Adriamycin, Etoposide and Cisplatin.
Irradiation represents another main pillar to cure a
tumor burden, so we addressed the question whether
AP-2 expression impinges on the sensitivity of the cells
towards ionizing radiaton. The ΔAP-2g expressing clones
displayed significantly (clone Δ#7: p = 0.0004; clone Δ#15:
p= 0.0005) reduced cell numbers 72 h after irrradiation
with 105 Gray compared to controls, as revealed by
Giemsa-staining (Figure 4A, C). Hence, repression of AP-2
function resulted in increased sensitivity towards ionizing
radiation and we conclude that expression of AP-2 genes
might confer a selective advantage to breast tumor cells
towards chemotherapeutic agents and irradiation.
Interference with AP-2 proteins causes a reduction in
proliferation rate and leads to induction of apoptosis
To address the question whether interference with AP-2
proteins had an influence on the proliferation rate of
Thewes et al. BMC Cancer 2010, 10:192
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Page 8 of 15N202.1A breast cancer cells, we subjected them to
“Click iT™"(Invitrogen) assays which selectively stain
cells in S-phase. We detected a decrease in proliferation
rate of approximately 30% in clones expressing ΔAP-2g
compared to uninduced und control cells (Figure 5A).
These results suggest that AP-2 proteins mediate pro-
proliferative functions.
After interference with AP-2 transcription factors we
observed changes in morphology of the N202.1A cells.
After interference for 96 hrs small protrusions (blebs)
on the plasma membrane could be detected (Figure 5B,
arrow). These protrusions could be verified using Scan-
ning (Figure 5D) and Transmission (Figure 5F) Electron
Microscopy and were not seen in uninduced clones
Figure 3 Microarray analysis validation and functional network for ΔAP-2g/EGFP- expressing N202.1A breast cancer cells. (A) Chromatin
from N202.1a cells was cross-linked to proteins, extracted and immunoprecipitated with either AP-2a (H-79) or AP-2g (6E/4) Abs or non-specific
rabbit- or mouse-IgG (negative isotype controls) or H3-histone or RNA-polymerase II Abs (positive controls). DNA was analyzed by PCR, using
primers flanking the AP-2 putative binding sites in Ctgf and Tnfaip3 promoters. Input: non immunoprecipitated DNA. (B) Microarray data
(additional file 1: Table S1 and Table 1) were validated by qRT-PCR performed in triplicate for 9 genes on three different RNA preparations from
ΔAP-2g/EGFP- (Δ#7; Δ#15) or EGFP- (Co#5; Co#11) expressing N202.1A clones. Black bars: microarray results; Dark grey bars: qRT-PCR of Δ#7 and
Δ#15 clones versus Co#5 and Co#11 clones; Light grey bars: qRT-PCR Δ#7 clone versus Co#11 clone. The GAPDH gene was used as an internal
control to normalize the data. Microarray analysis and qRT-PCR-fold changes are shown for each validated gene as average values. Bars represent
± standard error. (C) Functional network which connects the identified AP-2-regulated genes involved in “cell death” taken in part from analyses
carried on with Ingenuity™ Pathway Analysis. Legend: Continuous grey lines indicate direct interactions experimentally proven; dashed grey lines
represent potential indirect connections; dashed black lines represent potential indirect connections obtained from our microarray results
considering only Fold Changes > 2. The green and red symbols represent down- and up-regulations, respectively, while the white symbols
indicate genes absent in the dataset but related with the microarray genes as indicated from the literature. Blue checkmarks indicate the genes
verified by qRT-PCR in (B).
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Page 9 of 15(data not shown) or controls (Figure 5C,E,G). To ascer-
tain if the blebbing was based on changes in the actin
cytoskeleton, actin fibers were stained with Phalloidin
96 h after addition of doxycycline. However, we could
not detect structural changes of the actin cytosceleton
(not shown). This suggests that vesicle formation upon
interference with AP-2 function does not involve the
modification of actin cytoskeleton structure.
We reasoned that the blebs caused by ΔAP-2g expres-
sion might represent apoptotic bodies and therefore
checked for other apoptotic markers. First, activity of
Caspase 3/7 was measured as an early marker of apop-
tosis. Untreated clones were compared to doxycycline-
treated clones and Caspase 3/7 activity was quantified.
Long-time interference with AP-2 function (96 hrs)
resulted in a marked increase (p = 0.045 for Δ#7) in
Caspase 3/7 activity compared to uninduced and control
cells (Figure 6A). Furthermore, a fraction of cells expres-
sing ΔAP-2g were positive for AnnexinV3.18 staining
(Figure 6B-G) which represents another indicator of
apoptosis. The morphological changes caused by treat-
ment with the apoptosis-inducer Staurosporine were
similar to the blebbing seen upon expression of ΔAP-2g,
suggesting that the ΔAP-2g expressing cells indeed are
undergoing apoptosis (Figure 6E-G, compare to 6B-D).
To summarize our findings, interference with AP-2
transcription factors in N202.1A breast cancer cells
resulted in AnnexinV3.18-positive blebbing cells and an
increase of Caspase 3/7 acitivity. This further verifies
the data from the whole genome expression profiling
and indicates that interference with AP-2 proteins sensi-
tizes N202.1A breast cancer cells to apoptosis, which
might be one reason for the increase in chemo- and
radiation-sensitivity observed upon functional impair-
ment of AP-2 transcriptional activity.
Discussion
Although single AP-2 proteins have been implicated in
tumorigenesis in various types of cancers, their concerted
action in initiation and progression of breast cancer is far
from being understood. Previous work put its focus on the
analysis of the role of single AP-2 isoforms in the etiology
of breast cancer. Using a dominant-negative AP-2 mutant,
we demonstrated that simultaneous interference with
both, AP-2a and AP-2g leads to a decrease in proliferation
and induction of apoptosis in N202.1A breast cancer cells.
Table 1 Cell death-related genes in ΔAP-2g/EGFP- expressingN202.1A cells
Accession Symbol Definition FC
NM_010217 Ctgf connective tissue growth factor (Ctgf), mRNA. 3,4
NM_008737.1 Nrp neuropilin (Nrp), mRNA. 3,3
NM_011338 Ccl9 chemokine (C-C motif) ligand 9 (Ccl9), mRNA. 3,3
NM_015786 Hist1h1c histone 1, H1c (Hist1h1c), mRNA. 3,1
NM_009160.1 Sftpd surfactant associated protein D (Sftpd), mRNA. 2,9
NM_008046.1 Fst follistatin (Fst), mRNA. 2,6
AK031617 Csnk2a1-rs3 casein kinase II, alpha 1 related sequence 3, mRNA 2,5
NM_010762.2 Mal myelin and lymphocyte protein, T-cell differentiation protein (Mal), mRNA. 2,5
NM_009397.2 Tnfaip3 tumor necrosis factor, alpha-induced protein 3 (Tnfaip3), mRNA. 2,5
NM_011580.1 Thbs1 thrombospondin 1 (Thbs1), mRNA. 2,3
NM_144516.1 Zmynd11 zinc finger, MYND domain containing 11, mRNA 2,3
NM_080428 Fbxw7 F-box and WD-40 domain protein 7, archipelago homolog (Drosophila) (Fbxw7), mRNA. 2,2
NM_145452 Rasa1 RAS p21 protein activator 1 (Rasa1), mRNA. 2,1
NM_133853.1 Magi3 membrane associated guanlylate kinase, WW and PDZ domain containig 3 2,0
NM_133738 Antxr2 anthrax toxin receptor 2, mRNA 2,0
NM_028390.1 Anln anillin, actin binding protein (scraps homolog, Drosophila) (Anln), mRNA. 1,9
NM_012019.2 Pdcd8 programmed cell death 8 (Pdcd8), mRNA. 1,9
NM_013822.2 Jag1 jagged 1 (Jag1), mRNA. 1,8
NM_010789.1 Meis1 myeloid ecotropic viral integration site 1 (Meis1), mRNA. 1,7
J05277.1 Hk1 hexokinase mRNA, complete cds. -2,0
NM_177089.3 Tacc1 Transforming, acidic coiled coil protein 1 -2,0
NM_010777.1 Mbp myelin basic protein (Mbp), mRNA. 2,5
XM_483957 Dyrk2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2, mRNA 2,5
NM_018781 Egr3 early growth response 3 (Egr3), mRNA. -2,7
NM_009153.1 Sema3b sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3B (Sema3b), mRNA.
-2,9
Microarray analysis (Illumina Ref-8 BeadChip) was performed on ΔAP-2g (Δ#7, Δ#15) or EGFP- (Co#5, Co#11) expressing N202.1A clones in triplicate and 25
modulated genes involved in cell death (6 decreased, 19 increased, see Methods) were found. FC = Fold change. p < 0.001; FC. +/- 1.5.
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Page 10 of 15Figure 4 Interference with AP-2 results in an increase in chemo- and radiation-sensitivity in N202.1A breast cancer cells. (A) N202.1A
cells were left untreated (-) or induced with doxycycline (+) for 96 h and then Adriamycin (0.3 μg/ml) was addded for 72 h (upper columns) or
irradiation of 105 Gy was applied (lower columns). Visualisation under the phasecontrast microscope 72 h after treatment with Adriamycin
revealed a significant increase in blebbing and dead cells in Δ#7 expressing ΔAP-2g (+dox) compared to uninduced (-dox) and Co#11 cells
(-/+dox). A decreased number of cells is also seen using Giemsa staining upon expression of ΔAP-2g in Δ#7 (+dox) in comparison to uninduced
cells and Co#5 cells. Phase contrast microscopy 72 h after irradiation revealed a higher amount of dead cells in Δ#7 compared to uninduced and
Co#11 cells (-/+ dox). Lower amounts of cells are also seen using Giemsa staining upon expression of Δ#7 (+dox) in comparison to uninduced
cells (-dox) and Co#11 (-/+dox). Scale Bar represents 50 μm. (B) Quantification of cell numbers shows a decrease in cell numbers of
approximately 50% following interference with AP-2 proteins (Δ#7, +dox). Cell numbers are normalized to PBS treated controls. P-value of
unpaired t-test is given, (n.s. not significant). (C) For determination of radiation-sensitivity the N202.1A clones are induced for 96 h or left
uninduced followed by irradiation with 105 Gy. Normalisation of cell numbers to uninduced controls revealed a significant decrease in cell
numbers upon expression of ΔAP-2 (Δ#7, +; Δ#15, +). P-value of unpaired t-test is given (n.s. not significant).
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Page 11 of 15Figure 5 Impairment of proliferation and enhanced apoptosis upon interference with AP-2 proteins in N202.1A breast cancer cells.
(A) Click-iT Edu assays to determine the amount of cells in S-phase upon expression of ΔAP-2g in N202.1A. Induced clones were normalized to
uninduced clones and the percentage of cells in S-phase determined. *:P < 0.01, **:P < 0.05, n.s.:not significant. (B, C) N202.1A breast tumor cells
were treated with doxycycline for 96 h and then subjected to fluorescence, SEM (D, E) and TEM (F, G) analyses. Upon expression of the
dominant-negative AP-2g mutant in N202.1A cells (B, D, F), membrane surface blebbing (indicated by the arrows) can be observed, while control
cells display a regular polygonal morphology (C, E, G). Scale Bar represents 20 μm.
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chemotherapeutic drugs and irradiation.
AP-2a and AP-2g were suggested to act as decisive
pacemakers for cellular fates such as proliferation, apop-
tosis and differentiation in the mammary epithelium
under physiological conditions [5,20]. Therefore, their
inappropriate spatio-temporal expression might contri-
bute to malignant transformation. While in the normal
breast tissue AP-2a and AP-2g show non-overlapping
expression patterns [5], coexpression of AP-2a and
AP-2g was detected in undifferentiated breast carcino-
mas [4]. There is increasing evidence that the net out-
come whether a cell proliferates, undergoes apoptosis or
differentiates depends on the balance of various AP-2
proteins [22]. Here, interference with AP-2 proteins
using a dominant-negative AP-2 mutant in N202.1A
breast cancer cells resulted in a decreased proliferation
rate. Remarkably, overexpression of AP-2g in the mam-
mary gland using a transgenic mouse approach caused
an increase in proliferation as well [20], highlighting the
notion that certain AP-2 proteins might trigger
proliferation.
Wajapeyee et al. correlated increased AP-2a expression
with an enhanced rate of apoptosis after treatment with
cytostatic compounds [7,8]. Our results, however, suggest
that global interference with AP-2 proteins rather sensi-
tizes cells to apoptosis and anticancer treatment regimen.
We obtained conflicting results to those reported for the
function of AP-2a alone because we could detect apopto-
sis and an increased sensitivity towards chemotherapeutic
drugs and irradiation after global interference with AP-2
proteins. Our approach benefits from the fact that the
dominant-negative AP-2 mutant presumably interferes
with all AP-2 homo- and heterodimers present in
N202.1A breast cancer cells, which possibly occupy dif-
ferent target gene promoters than AP-2a alone. While
this approach can not distinguish between the functions
of individual AP-2 family members, it suggests that
Figure 6 N202.1A breast cancer cells display membrane-blebbing of upon interference with AP-2 proteins. (A) N202.1A breast cancer
cells were treated with doxycycline for 96 h and Caspase 3/7 activity was quantified using an artificial Caspase 3/7 luminogenic substrate.
Induced cells (+dox) expressing the dominant-negative AP-2g mutant (Δ#7, Δ#15) display a higher Caspase 3/7 activity compared to uninduced
cells (-dox) and Co#5, Co#11(-/+dox) cells. Results were derived from three independent experiments each. P-value of unpaired t-test is given
(n.s. not significant). (B-G) AnnexinVC3.18-staining. N202.1A breast cancer cells are induced for 96 h using doxycycline and then stained with
AnnexinV-conjugated Cy3.18 and visualized using fluorescence (B, D, E, G) or phase-contrast optics (C, D, F, G). Cells showing excessive blebbing
at the membrane surface following long-term expression of the dominant-negative AP-2 mutant (B-D) are AnnexinV-positive (indicated by the
arrows). Control cells treated with Staurosporine as classical inducer of apoptosis morphologically resemble the cells after interference with AP-2
function and are also AnnexinV-positive (E-G) indicating that it is an apoptosis-associated process. Scale Bar represents 10 μm.
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Page 13 of 15interfering with AP-2g may sensitize to apoptosis even in
the absence of functional AP-2a.
The whole genome expression analysis revealed 139
differentially expressed genes upon interference with
AP-2 proteins. Their function might explain the
decrease in proliferation rate and at the same time the
increase in chemo- and radiation-sensitivity upon
repression of AP-2 function also based on modulations
of some of these genes previously found following che-
mical and genetic perturbations [25]. On mRNA level
the following genes were found upregulated upon inter-
ference with AP-2 function suggesting that AP-2 pro-
teins act as repressors of these genes: Connective Tissue
Growth Factor (CTGF) is described to suppress prolif-
eration in breast cancer cells and other tumor entities
and induces apoptosis at least in part by activation of
caspase-3 [31-33]. Moreover, low expression levels of
CTGF in breast cancer patients have been correlated
with a poorer clinical outcome [34]. Neuropilin 1
(NRP-1) receptor has been described to be involved in
induction of apoptosis in breast cancer cell lines by inhi-
biting the Akt-signaling pathway [35,36]. The tumor
suppressor gene Tumor necrosis factor, alpha-induced
protein 3 (Tnfaip3) is an inhibititor of the pro-survival
activity of NFB [37].
Remarkably, the ATP-binding-cassette, subfamilyB
(MDR/TAP) member 9/GSTA3 was downregulated upon
interference with AP-2 function. It is member of a family,
which has been shown to contribute to the Multidrug
Resistance (MDR) phenotype [30]. Additionally this efflux
transporter family has been reported to detoxify reactive
oxygen species (ROS) generated by irradiation, [29] which
is a potential mechanism how tumor cells acquire resis-
tance towards irradiation-induced damage. This might
represent a mechanism of sensitization of N202.1A breast
cancer cells towards chemotherapeutic drugs and irradia-
tion caused by the abrogation of AP-2 function.
According to the analysis using ingenuity software, the
AP-2 target genes predominantly cluster to NFB,
Tp-53, Ras signalling and Calcium signalling. In sum-
mary the concerted deregulation of the candidate genes
might render cells more susceptible to apoptosis thus
resulting in an increased sensitivity towards chemothera-
peutic drugs and irradiation. It remains to be elucidated,
whether the candidate genes are direct targets of AP-2
transcription factors or are regulated by an indirect sec-
ondary mechanism.
Conclusions
The simultaneous expression of AP-2 transcription fac-
tors in breast cancer cells mediates pro-proliferative
and anti-apoptotic functions. In addition they contri-
bute to chemo- and radiation resistance of breast
cancer cells. Thus, interference with AP-2 function
could increase the sensitivity of tumor cells to thera-
peutic intervention.
Additional file 1: Table S1: Differentially expressed genes in ΔAP-2g/
EGFP-expressing N202.1A breast cancer cells. Microarray analysis
(Illumina Ref-8 BeadChip) was performed on ΔAP-2g/EGFP- (Δ#7, Δ#15) or
EGFP- (Co#5, Co#11) expressing N202.1A clones in triplicate and 139
modulated genes were found (49 decreased, 90 increased, see Methods).
FC = Fold change. p < 0.001; FC. +/- 1.5. Functions: more than one Gene
Ontology (GO) category was found in some cases. Genes marked in Red
display conserved AP-2 binding sites between mouse and human.
Numbers and relative location of AP-2 binding site is given (n.d. = not
done).
Additional file 2: Table S2: Gene/Gene Set overlap matrix derived
by using the datasets deposited in the Molecular Signatures
Database. Row (A) and (B) presents the results of 72 genes identified in
the screen here in relation to list all the datasets relevant to the analysis
(C-V). The spreadsheet (Overlapgenset) identifies the abbreviations used
in (C-V). Red boxes indicate overexpression, green boxes indicate
downregulation (Yellow - no information deposited).
Acknowledgements
We thank Cäcilia Hennes and Jörg Bedorf for excellent technical assistance
with the SEM and TEM analyses and Professor E. Medico and Dr D.
Cantarella for Illumina microarray data generation and analyses. We thank
Dr. Jutta Kirfel for discussing results. We are grateful to P.-L. Lollini for
kindly providing N202.1A cells. This work was supported by DFG Grant
Scho 503/6 and 503/7 and the Bonner Forum Biomedizin to HS and by
Regione Piemonte Ricerca Scientifica Applicata (CIPE2004) to DT. FO is a
fellow of the Regione Piemonte. Ingenuity Pathway Analysis Systems: free
trial to FO.
Author details
1Department of Developmental Pathology, Institute of Pathology, University
of Bonn, Medical School, Germany.
2Molecular Biotechnology Center (MBC)
and Department of Oncological Sciences, University of Turin, Via Nizza, 52,
10126 Torino, Italy.
3Center for Complex Systems in Molecular Biology and
Medicine, University of Turin, Via Acc. Albertina, 13, 10023 Torino, Italy.
4Department of Cell Biology, University of Bonn, Germany.
5Department of
Radiology, University of Bonn, Medical School, Germany.
6Division Molecular
Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
7National Centre for Biomedical Engineering Science, National University of
Ireland, Galway, Ireland.
Authors’ contributions
VT constructed the vectors, generated the cells, performed the induction,
radiation and chemotheraphy experiments and writing. FO performed array
and ChIP-analyses bioinformatics and interpretation, writing and revision. RJ
contributed to conception, acquisition of data, interpretation and writing
and performed RNA isolation and northern blots. DE contributed to
conception and design, bioinformatics, interpretation, writing and revision of
data. GK helped with TEM analyses. SS performed co-immunoprecepitation
and western-blot. SG helped with the radiation experiments, DT contributed
to interpretation, writing and revision, HS contibuted to conception and
design, interpretation, writing and revision. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 July 2009 Accepted: 11 May 2010 Published: 11 May 2010
References
1. Eckert D, Buhl S, Weber S, Jager R, Schorle H: The AP-2 family of
transcription factors. Genome Biol 2005, 6(13):246.
Thewes et al. BMC Cancer 2010, 10:192
http://www.biomedcentral.com/1471-2407/10/192
Page 14 of 152. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC: A family of AP-2
proteins regulates c-erbB-2 expression in mammary carcinoma.
Oncogene 1996, 13(8):1701-1707.
3. Pellikainen JM, Kosma VM: Activator protein-2 in carcinogenesis with a
special reference to breast cancer–a mini review. Int J Cancer 2007,
120(10):2061-2067.
4. Friedrichs N, Jager R, Paggen E, Rudlowski C, Merkelbach-Bruse S, Schorle H,
Buettner R: Distinct spatial expression patterns of AP-2alpha and AP-
2gamma in non-neoplastic human breast and breast cancer. Mod Pathol
2005, 18(3):431-438.
5. Friedrichs N, Steiner S, Buettner R, Knoepfle G: Immunohistochemical
expression patterns of AP2alpha and AP2gamma in the developing fetal
human breast. Histopathology 2007, 51(6):814-823.
6. Hilger-Eversheim K, Moser M, Schorle H, Buettner R: Regulatory roles of
AP-2 transcription factors in vertebrate development, apoptosis and cell-
cycle control. Gene 2000, 260(1-2):1-12.
7. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K: Apoptosis
induction by activator protein 2alpha involves transcriptional repression
of Bcl-2. J Biol Chem 2006, 281(24):16207-16219.
8. Wajapeyee N, Raut CG, Somasundaram K: Activator protein 2alpha status
determines the chemosensitivity of cancer cells: implications in cancer
chemotherapy. Cancer Res 2005, 65(19):8628-8634.
9. Zeng YX, Somasundaram K, el-Deiry WS: AP2 inhibits cancer cell growth
and activates p21WAF1/CIP1 expression. Nat Genet 1997, 15(1):78-82.
10. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC:
Immunohistochemical analysis reveals a tumour suppressor-like role for
the transcription factor AP-2 in invasive breast cancer. J Pathol 1999,
189(4):514-520.
11. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S: Identification of novel
deletion regions on chromosome arms 2q and 6p in breast carcinomas
by amplotype analysis. Genes Chromosomes Cancer 2001, 30(2):113-122.
12. Zhang J, Brewer S, Huang J, Williams T: Overexpression of transcription
factor AP-2alpha suppresses mammary gland growth and
morphogenesis. Dev Biol 2003, 256(1):127-145.
13. McPherson LA, Loktev AV, Weigel RJ: Tumor suppressor activity of
AP2alpha mediated through a direct interaction with p53. J Biol Chem
2002, 277(47):45028-45033.
14. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK,
Eskelinen MJ, Kosma VM: p21WAF1 expression in invasive breast cancer
and its association with p53, AP-2, cell proliferation, and prognosis. J
Clin Pathol 2003, 56(3):214-220.
15. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS,
Pinkel D, Gray JW, Waldman FM: Detection and mapping of amplified
DNA sequences in breast cancer by comparative genomic hybridization.
Proc Natl Acad Sci USA 1994, 91(6):2156-2160.
16. Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R,
Kowbel D, Shadravan F, Hintz M, Kuo WL, et al: Increased copy number at
20q13 in breast cancer: defining the critical region and exclusion of
candidate genes. Cancer Res 1994, 54(16):4257-4260.
17. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI,
Hurst HC: Overexpression of TFAP2C in invasive breast cancer correlates
with a poorer response to anti-hormone therapy and reduced patient
survival. J Pathol 2009, 217(1):32-41.
18. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K: Wwox
and Ap2gamma expression levels predict tamoxifen response. Clin
Cancer Res 2007, 13(20):6115-6121.
19. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC:
Chromosomal mapping of the human and mouse homologues of two
new members of the AP-2 family of transcription factors. Genomics 1996,
35(1):262-264.
20. Jager R, Werling U, Rimpf S, Jacob A, Schorle H: Transcription factor AP-
2gamma stimulates proliferation and apoptosis and impairs
differentiation in a transgenic model. Mol Cancer Res 2003, 1(12):921-929.
21. Jager R, Friedrichs N, Heim I, Buttner R, Schorle H: Dual role of AP-
2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res
Treat 2005, 90(3):273-280.
22. Richardson BD, Cheng YH, Langland RA, Handwerger S: Differential
expression of AP-2gamma and AP-2alpha during human trophoblast
differentiation. Life Sci 2001, 69(18):2157-2165.
23. Bookout AL, Mangelsdorf DJ: Quantitative real-time PCR protocol for
analysis of nuclear receptor signaling pathways. Nucl Recept Signal 2003,
1:e012.
24. Chudin E, Kruglyak S, Baker SC, Oeser S, Barker D, McDaniel TK: A model of
technical variation of microarray signals. J Comput Biol 2006,
13(4):996-1003.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
26. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A,
Ricci C, De Vecchi R, Invernizzi AM, et al: p185(neu) protein is required for
tumor and anchorage-independent growth, not for cell proliferation of
transgenic mammary carcinoma. Int J Cancer 2000, 87(2):186-194.
27. Williams T, Tjian R: Characterization of a dimerization motif in AP-2 and
its function in heterologous DNA-binding proteins. Science 1991,
251(4997):1067-1071.
28. Zhu CH, Domann FE: Dominant negative interference of transcription
factor AP-2 causes inhibition of ErbB-3 expression and suppresses
malignant cell growth. Breast Cancer Res Treat 2002, 71(1):47-57.
29. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family:
regulation of GST and the contribution of the isoenzymes to cancer
chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995,
30(6):445-600.
30. Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, Gaudio E:
[MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic
implications]. Clin Ter 2003, 154(5):325-335.
31. Hishikawa K, Nakaki T, Fujii T: Connective tissue growth factor induces
apoptosis via caspase 3 in cultured human aortic smooth muscle cells.
Eur J Pharmacol 2000, 392(1-2):19-22.
32. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Fujii T, Luscher TF:
Overexpression of connective tissue growth factor gene induces
apoptosis in human aortic smooth muscle cells. Circulation 1999,
100(20):2108-2112.
33. Szeto CC, Chow KM, Lai KB, Szeto CY, Kwan BC, Li PK: Connective tissue
growth factor is responsible for transforming growth factor-beta-
induced peritoneal mesothelial cell apoptosis. Nephron Exp Nephrol 2006,
103(4):e166-174.
34. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE:
Differential expression of the CCN family members Cyr61, CTGF and Nov
in human breast cancer. Endocr Relat Cancer 2004, 11(4):781-791.
35. Castro-Rivera E, Ran S, Brekken RA, Minna JD: Semaphorin 3B inhibits the
phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung
and breast cancer cells. Cancer Res 2008, 68(20):8295-8303.
36. Castro-Rivera E, Ran S, Thorpe P, Minna JD: Semaphorin 3B (SEMA3B)
induces apoptosis in lung and breast cancer, whereas VEGF165
antagonizes this effect. Proc Natl Acad Sci USA 2004, 101(31):11432-11437.
37. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A,
McKenna R, Koeffler HP: Suppression of cell proliferation and signaling
transduction by connective tissue growth factor in non-small cell lung
cancer cells. Mol Cancer Res 2006, 4(8):591-598.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/192/prepub
doi:10.1186/1471-2407-10-192
Cite this article as: Thewes et al.: Interference with Activator Protein-2
transcription factors leads to induction of apoptosis and an increase in
chemo- and radiation-sensitivity in breast cancer cells. BMC Cancer 2010
10:192.
Thewes et al. BMC Cancer 2010, 10:192
http://www.biomedcentral.com/1471-2407/10/192
Page 15 of 15